SCHEMBL2839100

SCHEMBL2839100

CC1(COc2ccc(C(O)C(NC(=O)OC(C)(C)C)c3ccc(Cl)c(Cl)c3)cc2)COC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.40
S1PR3 Q99500 2/20 0.39
SLC5A1 P13866 1/20 0.35
SLC5A2 P31639 1/20 0.35
CACNA1H O95180 5/20 0.35
P2RX3 P56373 1/20 0.34
P2RX2 Q9UBL9 1/20 0.34
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
CACNA1G O43497 1/20 0.33
CACNA1I Q9P0X4 1/20 0.33
FFAR1 O14842 3/20 0.33
CHEK1 O14757 1/20 0.33
CHEK2 O96017 1/20 0.33
AKT1 P31749 1/20 0.33
AAK1 Q2M2I8 1/20 0.33
SCN1A P35498 1/20 0.33
SCN5A Q14524 1/20 0.33
SCN8A Q9UQD0 1/20 0.33
PDE2A O00408 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2837534 0.89 SCN1A (0.39) ACACBS1PR3SLC5A1SLC5A2CACNA1H
SCHEMBL2836702 0.85 S1PR3 (0.44) ACACBS1PR3SLC5A1SLC5A2CACNA1H
SCHEMBL2836695 0.79 S1PR3 (0.41) ACACBS1PR3SLC5A1SLC5A2CACNA1H
SCHEMBL3376605 0.78 ACACB (0.46) ACACBS1PR3CACNA1HCACNA1GCACNA1I
SCHEMBL3376606 0.78 ACACB (0.46) ACACBS1PR3CACNA1HCACNA1GCACNA1I
SCHEMBL2842417 0.77 S1PR3 (0.43) S1PR3AAK1
SCHEMBL3794881 0.77 ACACB (0.37) ACACBSLC5A1SLC5A2CACNA1HNPC1
SCHEMBL2834220 0.77 S1PR3 (0.42) S1PR3AAK1
SCHEMBL2837598 0.77 S1PR3 (0.42) S1PR3AAK1
SCHEMBL2833723 0.71 S1PR3 (0.50) S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 ACACB 996/4885S1PR3 2311/4885SLC5A1 43/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 ACACB 996/4885S1PR3 2311/4885SLC5A1 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.